At a glance
ClinicalIndex Comparison RecordN/ACompleted· 16 target
Drug / intervention
Cirrus™ HD-OCT, Carl Zeiss Meditec AGdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reproducibility of Retinal Thickness and Volume Measurements Determined With the Cirrus Spectral Domain OCT
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery·observational·Posted Mar 26, 2008·Updated Jul 22, 2008
In Brief
An observational study evaluating Cirrus™ HD-OCT, Carl Zeiss Meditec AG for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
In this study the reproducibility of optical coherence tomography measurements should be evaluated.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
TodayJul 2026
First PostedMar 26, 2008
TodayJul 2, 2026
Posted 18.3 years ago
Interventions
Cirrus™ HD-OCT, Carl Zeiss Meditec AGdevice
the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.